Adjuvant Chemotherapy versus Concurrent Chemoradiotherapy for Surgically Treated T1b Uterine Cervical Cancer: A Propensity Score Matched Analysis of the JSOG Nationwide Data
Annals of Surgical Oncology · 2025
DOI: 10.1245/s10434-024-16638-2 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Annals of Surgical Oncology, 2025. Verfasst von Yusuke Tanaka und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Osaka Rosai Hospital, Sakai, Osaka, Japan. ytanaka@osakah.johas.go.jp. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms, Chemoradiotherapy, Carcinoma, Squamous Cell, Hysterectomy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 18 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
OBJECTIVE: The aim of this study was to assess the effect of postoperative chemotherapy on the survival of surgically treated patients with T1b uterine cervical cancer. METHODS: Overall, 1687 patients with T1b cervical cancer who received concurrent chemoradiotherapy (CCRT) or chemotherapy as postoperative adjuvant therapy were retrospectively analyzed using the Japan Society of Obstetrics and Gynecology cancer registry program data from 2015 to 2016. After propensity score matching, overall survival (OS) was compared between 643 patients treated with CCRT and 643 patients treated with chemotherapy. RESULTS: OS was significantly higher in the chemotherapy group than in the CCRT group (hazard ratio [HR] 0.653, 95% confidence interval [CI] 0.448 - 0.953; p = 0.026). In the subgroup analysis, patients with squamous histology and large tumor size (>4 cm) and without lymph node metastasis can benefit from chemotherapy in terms of OS (HR 0.53, 95% CI 0.29-0.95; HR 0.49, 95% CI 0.25-0.95; and HR 0.54, 95% CI 0.33-0.88, respectively). CONCLUSION: Patients with cervical cancer with squamous histology, large tumor size and negative lymph node metastasis can benefit from postoperative chemotherapy in terms of survival. Tumor characteristics could be associated with the effect of postoperative adjuvant chemotherapy on survival.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, Osaka Rosai Hospital, Sakai, Osaka, Japan. ytanaka@osakah.johas.go.jp.
- Department of Obstetrics and Gynecology, Osaka Rosai Hospital, Sakai, Osaka, Japan.
- Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
Zitieren
APA
Tanaka, Y., Higami, S., Ishii, T., Shiki, Y., Ueda, Y., & Kimura, T. (2025). Adjuvant Chemotherapy versus Concurrent Chemoradiotherapy for Surgically Treated T1b Uterine Cervical Cancer: A Propensity Score Matched Analysis of the JSOG Nationwide Data. Annals of Surgical Oncology. https://doi.org/10.1245/s10434-024-16638-2
Vancouver
Tanaka Y, Higami S, Ishii T, Shiki Y, Ueda Y, Kimura T. Adjuvant Chemotherapy versus Concurrent Chemoradiotherapy for Surgically Treated T1b Uterine Cervical Cancer: A Propensity Score Matched Analysis of the JSOG Nationwide Data. Annals of Surgical Oncology. 2025. doi:10.1245/s10434-024-16638-2
BibTeX
@article{Tanaka2025,
author = {Tanaka, Yusuke and Higami, Shota and Ishii, Tomomi and Shiki, Yasuhiko and Ueda, Yutaka and Kimura, Tadashi},
title = {Adjuvant Chemotherapy versus Concurrent Chemoradiotherapy for Surgically Treated T1b Uterine Cervical Cancer: A Propensity Score Matched Analysis of the JSOG Nationwide Data},
journal = {Annals of Surgical Oncology},
year = {2025},
doi = {10.1245/s10434-024-16638-2}
}
EUVIMED